BRD4 and gastrointestinal stromal tumor: Our data illustrate that the inhibition of BRD4 has a robust growth inhibitory effect on GIST cells in vitro, suggesting that secondary imatinib resistance is a result of PI3K/AKT signalling pathway activation.